The radioligand therapy market is projected to reach $45.6 billion by 2036, at a CAGR of 16.8% from 2026 to 2036. The growth of this market is primarily fueled by the increasing prevalence of cancer, growing adoption of precision oncology, and expanding PSMA-targeted therapies. Additionally, earlier-line treatment approvals, expansion into new molecular targets beyond PSMA and SSTR, and development of next-generation alpha-emitter radioligands are expected to create substantial growth opportunities for market participants.
The key players operating in the radioligand therapy market are Novartis AG (Switzerland), Eli Lilly and Company (U.S.), POINT Biopharma Global Inc. (U.S.), Telix Pharmaceuticals Limited (Australia), ITM Isotope Technologies Munich SE (Germany), RayzeBio, Inc. (Bristol Myers Squibb) (U.S.), Perspective Therapeutics, Inc. (U.S.), Fusion Pharmaceuticals Inc. (AstraZeneca) (Canada), Curium Pharma (France), Eckert & Ziegler SE (Germany), Lantheus Holdings, Inc. (U.S.), RadioMedix Inc. (U.S.), Orano Med (France), and Sofie Biosciences, Inc. (U.S.).
The radioligand therapy market study presents historical market data value (2025), estimated current data (2026), and forecasts for 2036. This market is segmented by product/radioligand, radionuclide, radiation type, molecular target, indication, treatment line, route of administration, end user, and geography.
Among all the products, Lutetium-177 Vipivotide Tetraxetan (Pluvicto) is expected to account for the largest share of the radioligand therapy market in 2026. The dominant position of this segment is primarily attributed to its established commercial position in metastatic castration-resistant prostate cancer and its recently expanded label into pre-taxane patient populations. Actinium-225-based candidates such as Actinium-225 PSMA-617, however, are projected to register the fastest growth during the forecast period, driven by strong early clinical data and substantial pharmaceutical industry investment in alpha-emitter development.
Among all the radionuclides, Lutetium-177 is expected to account for the largest share of the radioligand therapy market in 2026, supported by its use in both Pluvicto and Lutathera, the two leading commercially approved radioligand therapies. Actinium-225, however, is projected to register the fastest growth, driven by expanding clinical development of alpha-emitter therapies across multiple molecular targets.
Among all the molecular targets, PSMA is expected to account for the largest share of the market in 2026, driven by the commercial success of PSMA-targeted therapies in prostate cancer and the depth of the PSMA-targeted clinical pipeline. FAP, meanwhile, is projected to register the fastest growth, reflecting growing clinical interest in fibroblast activation protein as a target expressed across multiple solid tumor types.
Among all the indications, Prostate Cancer is expected to account for the largest share of the market in 2026, led by metastatic castration-resistant prostate cancer and reflecting Pluvicto's established commercial position and expanding label. Other Solid Tumors, on the other hand, are projected to register the fastest growth, driven by expanding clinical development of radioligand therapies beyond prostate cancer and neuroendocrine tumors.
Among all the end users, Tertiary Care Academic & Comprehensive Cancer Centers are expected to account for the largest share of the market in 2026, reflecting their established nuclear medicine infrastructure and radiation safety capabilities required for radioligand therapy administration. Specialized Nuclear Medicine Centers, meanwhile, are projected to register the fastest growth, driven by increasing investment in dedicated radioligand therapy treatment infrastructure.
Among all the geographies, North America is expected to account for the largest share of the radioligand therapy market in 2026, underpinned by leading RLT developers, established nuclear medicine infrastructure, expanding radiopharmaceutical manufacturing capacity, and a favorable regulatory environment, including the FDA's July 2026 approval of Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer. Asia-Pacific, however, is projected to register the highest CAGR during the forecast period, supported by expanding RLT regulatory pathways, increasing radiopharmaceutical manufacturing capacity, and growing adoption of molecular imaging and precision oncology across China, Japan, India, and South Korea.
The key players operating in the radioligand therapy market are Novartis AG (Switzerland), Eli Lilly and Company (U.S.), POINT Biopharma Global Inc. (U.S.), Telix Pharmaceuticals Limited (Australia), ITM Isotope Technologies Munich SE (Germany), RayzeBio, Inc. (Bristol Myers Squibb) (U.S.), Perspective Therapeutics, Inc. (U.S.), Fusion Pharmaceuticals Inc. (AstraZeneca) (Canada), Curium Pharma (France), Eckert & Ziegler SE (Germany), Lantheus Holdings, Inc. (U.S.), RadioMedix Inc. (U.S.), Orano Med (France), and Sofie Biosciences, Inc. (U.S.).
The radioligand therapy market study presents historical market data value (2025), estimated current data (2026), and forecasts for 2036. This market is segmented by product/radioligand, radionuclide, radiation type, molecular target, indication, treatment line, route of administration, end user, and geography.
Among all the products, Lutetium-177 Vipivotide Tetraxetan (Pluvicto) is expected to account for the largest share of the radioligand therapy market in 2026. The dominant position of this segment is primarily attributed to its established commercial position in metastatic castration-resistant prostate cancer and its recently expanded label into pre-taxane patient populations. Actinium-225-based candidates such as Actinium-225 PSMA-617, however, are projected to register the fastest growth during the forecast period, driven by strong early clinical data and substantial pharmaceutical industry investment in alpha-emitter development.
Among all the radionuclides, Lutetium-177 is expected to account for the largest share of the radioligand therapy market in 2026, supported by its use in both Pluvicto and Lutathera, the two leading commercially approved radioligand therapies. Actinium-225, however, is projected to register the fastest growth, driven by expanding clinical development of alpha-emitter therapies across multiple molecular targets.
Among all the molecular targets, PSMA is expected to account for the largest share of the market in 2026, driven by the commercial success of PSMA-targeted therapies in prostate cancer and the depth of the PSMA-targeted clinical pipeline. FAP, meanwhile, is projected to register the fastest growth, reflecting growing clinical interest in fibroblast activation protein as a target expressed across multiple solid tumor types.
Among all the indications, Prostate Cancer is expected to account for the largest share of the market in 2026, led by metastatic castration-resistant prostate cancer and reflecting Pluvicto's established commercial position and expanding label. Other Solid Tumors, on the other hand, are projected to register the fastest growth, driven by expanding clinical development of radioligand therapies beyond prostate cancer and neuroendocrine tumors.
Among all the end users, Tertiary Care Academic & Comprehensive Cancer Centers are expected to account for the largest share of the market in 2026, reflecting their established nuclear medicine infrastructure and radiation safety capabilities required for radioligand therapy administration. Specialized Nuclear Medicine Centers, meanwhile, are projected to register the fastest growth, driven by increasing investment in dedicated radioligand therapy treatment infrastructure.
Among all the geographies, North America is expected to account for the largest share of the radioligand therapy market in 2026, underpinned by leading RLT developers, established nuclear medicine infrastructure, expanding radiopharmaceutical manufacturing capacity, and a favorable regulatory environment, including the FDA's July 2026 approval of Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer. Asia-Pacific, however, is projected to register the highest CAGR during the forecast period, supported by expanding RLT regulatory pathways, increasing radiopharmaceutical manufacturing capacity, and growing adoption of molecular imaging and precision oncology across China, Japan, India, and South Korea.
Key Questions Answered in the Report:
- What is the current revenue generated by the radioligand therapy market globally?
- At what rate is the radioligand therapy market demand projected to grow for the next 10 years?
- What are the historical market sizes and growth rates of the radioligand therapy market?
- What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
- Which segments in terms of product/radioligand, radionuclide, radiation type, molecular target, indication, treatment line, and end user are expected to create major traction for the manufacturers in this market?
- What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the manufacturers operating in the radioligand therapy market?
- Who are the major players in the radioligand therapy market? What are their specific product offerings in this market?
- What are the recent strategic developments in the radioligand therapy market? What are the impacts of these strategic developments on the market?
Table of Contents
1 INTRODUCTION
1.1 Market Definition
1.2 Market Ecosystem
1.3 Currency and Limitations
1.3.1 Currency
1.3.2 Limitations
1.4 Key Stakeholders
1.2 Market Ecosystem
1.3 Currency and Limitations
1.3.1 Currency
1.3.2 Limitations
1.4 Key Stakeholders
2 RESEARCH METHODOLOGY
2.1 Research Approach
2.2 Data Collection & Validation Process
2.2.1 Secondary Research
2.2.2 Primary Research & Validation
2.2.2.1 Primary Interviews with Radioligand Therapy Experts
2.2.2.2 Country-/Region-Level Analysis
2.3 Market Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.3.3 Forecast Methodology
2.4 Data Triangulation
2.5 Assumptions
2.2 Data Collection & Validation Process
2.2.1 Secondary Research
2.2.2 Primary Research & Validation
2.2.2.1 Primary Interviews with Radioligand Therapy Experts
2.2.2.2 Country-/Region-Level Analysis
2.3 Market Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.3.3 Forecast Methodology
2.4 Data Triangulation
2.5 Assumptions
4 MARKET OVERVIEW
4.1 Introduction
4.2 Radioligand Therapy Overview
4.2.1 Radioligand Therapy Concept
4.2.2 Targeted Radionuclide Therapy
4.2.3 Diagnostic-Therapeutic Pairing
4.2.4 Theranostics
4.2.5 Radioligand Therapy Treatment Workflow
4.2.6 Patient Selection
4.2.7 Dosimetry
4.2.8 Administration & Treatment Monitoring
4.3 Radioligand Therapy Components
4.3.1 Targeting Ligands
4.3.2 Chelators
4.3.3 Radionuclides
4.3.4 Linkers
4.3.5 Carrier Molecules
4.3.6 Diagnostic Counterparts
4.4 Market Dynamics
4.4.1 Drivers
4.4.1.1 Increasing Prevalence of Cancer
4.4.1.2 Growing Clinical Adoption of PSMA- and SSTR-Targeted Therapies
4.4.1.3 Increasing Adoption of Precision Oncology and PET-Based Patient Selection
4.4.1.4 Growing Pharmaceutical Investments in Radioligand Therapy
4.4.2 Restraints
4.4.2.1 Limited Availability of Therapeutic Radionuclides
4.4.2.2 Complex Manufacturing and Time-Critical Supply Chains
4.4.2.3 High Treatment Costs and Limited Nuclear Medicine Infrastructure
4.4.3 Opportunities
4.4.3.1 Expansion into Earlier Lines of Treatment
4.4.3.2 Development of Alpha-Emitter Radioligand Therapies
4.4.3.3 Emergence of New Molecular Targets Beyond Prostate Cancer and Neuroendocrine Tumors
4.4.3.4 Increasing Adoption in Emerging Markets
4.4.4 Challenges
4.4.4.1 Shortage of Trained Nuclear Medicine Workforce
4.4.4.2 Regulatory Complexity Across Countries
4.4.4.3 Patient Access and Reimbursement Challenges
4.5 Regulatory Landscape
4.5.1 U.S. Regulatory Landscape
4.5.2 European Regulatory Landscape
4.5.3 Asia-Pacific Regulatory Landscape
4.5.4 Radiopharmaceutical Manufacturing Requirements
4.5.5 Good Manufacturing Practices
4.5.6 Radiation Safety Regulations
4.5.7 Clinical Trial Requirements
4.5.8 Companion Diagnostic Requirements
4.6 Reimbursement Landscape
4.6.1 Reimbursement for Radioligand Therapy
4.6.2 Reimbursement for Diagnostic Imaging
4.6.3 Hospital-Based Reimbursement
4.6.4 Private Insurance Coverage
4.6.5 Government Reimbursement Programs
4.6.6 Patient Access Programs
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Buyers
4.7.2 Bargaining Power of Suppliers
4.7.3 Threat of Substitutes
4.7.4 Threat of New Entrants
4.7.5 Degree of Competition
4.8 Investment & Industry Trends
4.8.1 Pharmaceutical Investments in Radioligand Therapy
4.8.2 Radiopharmaceutical Manufacturing Investments
4.8.3 Radionuclide Production Investments
4.8.4 Alpha-Emitter Investments
4.8.5 Radioligand Therapy Acquisitions
4.8.6 Strategic Partnerships & Licensing
4.8.7 Expansion of Nuclear Medicine Infrastructure
4.8.8 Clinical Pipeline Expansion
4.2 Radioligand Therapy Overview
4.2.1 Radioligand Therapy Concept
4.2.2 Targeted Radionuclide Therapy
4.2.3 Diagnostic-Therapeutic Pairing
4.2.4 Theranostics
4.2.5 Radioligand Therapy Treatment Workflow
4.2.6 Patient Selection
4.2.7 Dosimetry
4.2.8 Administration & Treatment Monitoring
4.3 Radioligand Therapy Components
4.3.1 Targeting Ligands
4.3.2 Chelators
4.3.3 Radionuclides
4.3.4 Linkers
4.3.5 Carrier Molecules
4.3.6 Diagnostic Counterparts
4.4 Market Dynamics
4.4.1 Drivers
4.4.1.1 Increasing Prevalence of Cancer
4.4.1.2 Growing Clinical Adoption of PSMA- and SSTR-Targeted Therapies
4.4.1.3 Increasing Adoption of Precision Oncology and PET-Based Patient Selection
4.4.1.4 Growing Pharmaceutical Investments in Radioligand Therapy
4.4.2 Restraints
4.4.2.1 Limited Availability of Therapeutic Radionuclides
4.4.2.2 Complex Manufacturing and Time-Critical Supply Chains
4.4.2.3 High Treatment Costs and Limited Nuclear Medicine Infrastructure
4.4.3 Opportunities
4.4.3.1 Expansion into Earlier Lines of Treatment
4.4.3.2 Development of Alpha-Emitter Radioligand Therapies
4.4.3.3 Emergence of New Molecular Targets Beyond Prostate Cancer and Neuroendocrine Tumors
4.4.3.4 Increasing Adoption in Emerging Markets
4.4.4 Challenges
4.4.4.1 Shortage of Trained Nuclear Medicine Workforce
4.4.4.2 Regulatory Complexity Across Countries
4.4.4.3 Patient Access and Reimbursement Challenges
4.5 Regulatory Landscape
4.5.1 U.S. Regulatory Landscape
4.5.2 European Regulatory Landscape
4.5.3 Asia-Pacific Regulatory Landscape
4.5.4 Radiopharmaceutical Manufacturing Requirements
4.5.5 Good Manufacturing Practices
4.5.6 Radiation Safety Regulations
4.5.7 Clinical Trial Requirements
4.5.8 Companion Diagnostic Requirements
4.6 Reimbursement Landscape
4.6.1 Reimbursement for Radioligand Therapy
4.6.2 Reimbursement for Diagnostic Imaging
4.6.3 Hospital-Based Reimbursement
4.6.4 Private Insurance Coverage
4.6.5 Government Reimbursement Programs
4.6.6 Patient Access Programs
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Buyers
4.7.2 Bargaining Power of Suppliers
4.7.3 Threat of Substitutes
4.7.4 Threat of New Entrants
4.7.5 Degree of Competition
4.8 Investment & Industry Trends
4.8.1 Pharmaceutical Investments in Radioligand Therapy
4.8.2 Radiopharmaceutical Manufacturing Investments
4.8.3 Radionuclide Production Investments
4.8.4 Alpha-Emitter Investments
4.8.5 Radioligand Therapy Acquisitions
4.8.6 Strategic Partnerships & Licensing
4.8.7 Expansion of Nuclear Medicine Infrastructure
4.8.8 Clinical Pipeline Expansion
5 RADIOLIGAND THERAPY MARKET, BY PRODUCT/RADIOLIGAND
5.1 Introduction
5.2 Lutetium-177 Vipivotide Tetraxetan (Pluvicto)
5.3 Lutetium-177 Dotatate (Lutathera)
5.4 Radium-223 Dichloride (Xofigo)
5.5 Lutetium-177 Edotreotide (ITM-11)
5.6 Lutetium-177 Zadavotide Guraxetan (177Lu-PSMA-I&T)
5.7 Actinium-225 PSMA-617
5.8 FPI-2265
5.9 TLX591 (177Lu-Rosopatamab Tetraxetan)
5.10 225Ac-DOTATATE (RYZ101)
5.11 212Pb-DOTAMTATE (AlphaMedix)
5.12 67Cu-SAR-bisPSMA
5.13 Other Radioligand Therapies
5.2 Lutetium-177 Vipivotide Tetraxetan (Pluvicto)
5.3 Lutetium-177 Dotatate (Lutathera)
5.4 Radium-223 Dichloride (Xofigo)
5.5 Lutetium-177 Edotreotide (ITM-11)
5.6 Lutetium-177 Zadavotide Guraxetan (177Lu-PSMA-I&T)
5.7 Actinium-225 PSMA-617
5.8 FPI-2265
5.9 TLX591 (177Lu-Rosopatamab Tetraxetan)
5.10 225Ac-DOTATATE (RYZ101)
5.11 212Pb-DOTAMTATE (AlphaMedix)
5.12 67Cu-SAR-bisPSMA
5.13 Other Radioligand Therapies
6 RADIOLIGAND THERAPY MARKET, BY RADIONUCLIDE
6.1 Introduction
6.2 Lutetium-177 (Lu-177)
6.3 Actinium-225 (Ac-225)
6.4 Radium-223 (Ra-223)
6.5 Lead-212 (Pb-212)
6.6 Other Radionuclides
6.2 Lutetium-177 (Lu-177)
6.3 Actinium-225 (Ac-225)
6.4 Radium-223 (Ra-223)
6.5 Lead-212 (Pb-212)
6.6 Other Radionuclides
7 RADIOLIGAND THERAPY MARKET, BY RADIATION TYPE
7.1 Introduction
7.2 Beta Emitters
7.3 Alpha Emitters
7.4 Other Emitters (Including Auger Electron Emitters)
7.2 Beta Emitters
7.3 Alpha Emitters
7.4 Other Emitters (Including Auger Electron Emitters)
8 RADIOLIGAND THERAPY MARKET, BY MOLECULAR TARGET
8.1 Introduction
8.2 Prostate-Specific Membrane Antigen (PSMA)
8.3 Somatostatin Receptors (SSTR)
8.4 Bone Mineral (Hydroxyapatite)
8.5 Fibroblast Activation Protein (FAP)
8.6 Other Emerging Targets
8.2 Prostate-Specific Membrane Antigen (PSMA)
8.3 Somatostatin Receptors (SSTR)
8.4 Bone Mineral (Hydroxyapatite)
8.5 Fibroblast Activation Protein (FAP)
8.6 Other Emerging Targets
9 RADIOLIGAND THERAPY MARKET, BY INDICATION
9.1 Introduction
9.2 Prostate Cancer
9.2.1 Metastatic Castration-Resistant Prostate Cancer
9.2.2 Metastatic Hormone-Sensitive Prostate Cancer
9.3 Neuroendocrine Tumors
9.3.1 Gastrointestinal Neuroendocrine Tumors
9.3.2 Pancreatic Neuroendocrine Tumors
9.3.3 Lung & Other Neuroendocrine Tumors
9.4 Other Solid Tumors
9.5 Other Indications
9.2 Prostate Cancer
9.2.1 Metastatic Castration-Resistant Prostate Cancer
9.2.2 Metastatic Hormone-Sensitive Prostate Cancer
9.3 Neuroendocrine Tumors
9.3.1 Gastrointestinal Neuroendocrine Tumors
9.3.2 Pancreatic Neuroendocrine Tumors
9.3.3 Lung & Other Neuroendocrine Tumors
9.4 Other Solid Tumors
9.5 Other Indications
10 RADIOLIGAND THERAPY MARKET, BY TREATMENT LINE
10.1 Introduction
10.2 First-Line Therapy
10.3 Second-Line Therapy
10.4 Third-Line & Later Therapy
10.2 First-Line Therapy
10.3 Second-Line Therapy
10.4 Third-Line & Later Therapy
11 RADIOLIGAND THERAPY MARKET, BY END USER
11.1 Introduction
11.2 Academic & Comprehensive Cancer Centers
11.3 Community Hospitals
11.4 Specialized Nuclear Medicine Centers
11.5 Other End Users
11.2 Academic & Comprehensive Cancer Centers
11.3 Community Hospitals
11.4 Specialized Nuclear Medicine Centers
11.5 Other End Users
12 RADIOLIGAND THERAPY MARKET, BY GEOGRAPHY
12.1 Introduction
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 U.K.
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 Switzerland
12.3.7 Netherlands
12.3.8 Belgium
12.3.9 Sweden
12.3.10 Rest of Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Australia
12.4.6 Singapore
12.4.7 Taiwan
12.4.8 Rest of Asia-Pacific
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Argentina
12.5.4 Rest of Latin America
12.6 Middle East & Africa
12.6.1 U.A.E.
12.6.2 Saudi Arabia
12.6.3 Israel
12.6.4 South Africa
12.6.5 Rest of Middle East & Africa
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 U.K.
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 Switzerland
12.3.7 Netherlands
12.3.8 Belgium
12.3.9 Sweden
12.3.10 Rest of Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Australia
12.4.6 Singapore
12.4.7 Taiwan
12.4.8 Rest of Asia-Pacific
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Argentina
12.5.4 Rest of Latin America
12.6 Middle East & Africa
12.6.1 U.A.E.
12.6.2 Saudi Arabia
12.6.3 Israel
12.6.4 South Africa
12.6.5 Rest of Middle East & Africa
13 COMPETITIVE LANDSCAPE
13.1 Overview
13.2 Key Growth Strategies
13.3 Competitive Benchmarking
13.4 Competitive Dashboard
13.4.1 Market Leaders
13.4.2 Market Differentiators
13.4.3 Vanguards
13.4.4 Emerging Players
13.5 Market Ranking Analysis, By Key Player (2025)
13.5.1 Novartis AG (Switzerland) - Rank 1
13.5.2 Bayer AG (Germany) - Rank 2
13.5.3 Next Commercial Challengers
13.2 Key Growth Strategies
13.3 Competitive Benchmarking
13.4 Competitive Dashboard
13.4.1 Market Leaders
13.4.2 Market Differentiators
13.4.3 Vanguards
13.4.4 Emerging Players
13.5 Market Ranking Analysis, By Key Player (2025)
13.5.1 Novartis AG (Switzerland) - Rank 1
13.5.2 Bayer AG (Germany) - Rank 2
13.5.3 Next Commercial Challengers
14 COMPANY PROFILES
14.1 Novartis AG
14.1.1 Business Overview
14.1.2 Financial Overview
14.1.3 Radioligand Therapy Portfolio
14.1.4 Pipeline
14.1.5 Manufacturing Capabilities
14.1.6 Strategic Developments
14.1.7 SWOT Analysis
14.2 Bayer AG
14.2.1 Business Overview
14.2.2 Financial Overview
14.2.3 Radioligand Therapy Portfolio
14.2.4 Pipeline
14.2.5 Manufacturing Capabilities
14.2.6 SWOT Analysis
14.3 Eli Lilly and Company
14.3.1 Business Overview
14.3.2 Financial Overview
14.3.3 Radioligand Therapy Portfolio
14.3.4 Pipeline
14.3.5 Manufacturing Capabilities
14.3.6 Strategic Developments
14.3.7 SWOT Analysis
14.4 Bristol Myers Squibb Company (RayzeBio)
14.4.1 Business Overview
14.4.2 Financial Overview
14.4.3 Radioligand Therapy Portfolio
14.4.4 Pipeline
14.4.5 Manufacturing Capabilities
14.4.6 Strategic Developments
14.4.7 SWOT Analysis
14.5 AstraZeneca PLC (Fusion Pharmaceuticals)
14.5.1 Business Overview
14.5.2 Financial Overview
14.5.3 Radioligand Therapy Portfolio
14.5.4 Pipeline
14.5.5 Manufacturing Capabilities
14.5.6 Strategic Developments
14.5.7 SWOT Analysis
14.6 Telix Pharmaceuticals Limited
14.6.1 Business Overview
14.6.2 Financial Overview
14.6.3 Radioligand Therapy Portfolio
14.6.4 Pipeline
14.6.5 Manufacturing Capabilities
14.6.6 Strategic Developments
14.6.7 SWOT Analysis
14.7 ITM Isotope Technologies Munich SE
14.7.1 Business Overview
14.7.2 Radioligand Therapy Portfolio
14.7.3 Pipeline
14.7.4 Manufacturing Capabilities
14.7.5 Strategic Developments
14.7.6 SWOT Analysis
14.8 Curium
14.8.1 Business Overview
14.8.2 Radioligand Therapy Portfolio
14.8.3 Pipeline
14.8.4 Manufacturing Capabilities
14.8.5 Strategic Developments
14.8.6 SWOT Analysis
14.9 Lantheus Holdings, Inc.
14.9.1 Business Overview
14.9.2 Financial Overview
14.9.3 Radioligand Therapy Portfolio
14.9.4 Pipeline
14.9.5 Manufacturing Capabilities
14.9.6 Strategic Developments
14.9.7 SWOT Analysis
14.10 Perspective Therapeutics, Inc.
14.10.1 Business Overview
14.10.2 Financial Overview
14.10.3 Radioligand Therapy Portfolio
14.10.4 Pipeline
14.10.5 Manufacturing Capabilities
14.10.6 Strategic Developments
14.10.7 SWOT Analysis
14.11 Orano Med
14.11.1 Business Overview
14.11.2 Radioligand Therapy Portfolio
14.11.3 Pipeline
14.11.4 Manufacturing Capabilities
14.11.5 Strategic Developments
14.11.6 SWOT Analysis
14.12 RadioMedix, Inc.
14.12.1 Business Overview
14.12.2 Radioligand Therapy Portfolio
14.12.3 Pipeline
14.12.4 Manufacturing Capabilities
14.12.5 Strategic Developments
14.12.6 SWOT Analysis
14.13 Clarity Pharmaceuticals Ltd
14.13.1 Business Overview
14.13.2 Financial Overview
14.13.3 Radioligand Therapy Portfolio
14.13.4 Pipeline
14.13.5 Manufacturing Capabilities
14.13.6 Strategic Developments
14.13.7 SWOT Analysis
14.14 Sanofi
14.14.1 Business Overview
14.14.2 Financial Overview
14.14.3 Radioligand Therapy Portfolio
14.14.4 Pipeline
14.14.5 Strategic Developments
14.14.6 SWOT Analysis
14.1.1 Business Overview
14.1.2 Financial Overview
14.1.3 Radioligand Therapy Portfolio
14.1.4 Pipeline
14.1.5 Manufacturing Capabilities
14.1.6 Strategic Developments
14.1.7 SWOT Analysis
14.2 Bayer AG
14.2.1 Business Overview
14.2.2 Financial Overview
14.2.3 Radioligand Therapy Portfolio
14.2.4 Pipeline
14.2.5 Manufacturing Capabilities
14.2.6 SWOT Analysis
14.3 Eli Lilly and Company
14.3.1 Business Overview
14.3.2 Financial Overview
14.3.3 Radioligand Therapy Portfolio
14.3.4 Pipeline
14.3.5 Manufacturing Capabilities
14.3.6 Strategic Developments
14.3.7 SWOT Analysis
14.4 Bristol Myers Squibb Company (RayzeBio)
14.4.1 Business Overview
14.4.2 Financial Overview
14.4.3 Radioligand Therapy Portfolio
14.4.4 Pipeline
14.4.5 Manufacturing Capabilities
14.4.6 Strategic Developments
14.4.7 SWOT Analysis
14.5 AstraZeneca PLC (Fusion Pharmaceuticals)
14.5.1 Business Overview
14.5.2 Financial Overview
14.5.3 Radioligand Therapy Portfolio
14.5.4 Pipeline
14.5.5 Manufacturing Capabilities
14.5.6 Strategic Developments
14.5.7 SWOT Analysis
14.6 Telix Pharmaceuticals Limited
14.6.1 Business Overview
14.6.2 Financial Overview
14.6.3 Radioligand Therapy Portfolio
14.6.4 Pipeline
14.6.5 Manufacturing Capabilities
14.6.6 Strategic Developments
14.6.7 SWOT Analysis
14.7 ITM Isotope Technologies Munich SE
14.7.1 Business Overview
14.7.2 Radioligand Therapy Portfolio
14.7.3 Pipeline
14.7.4 Manufacturing Capabilities
14.7.5 Strategic Developments
14.7.6 SWOT Analysis
14.8 Curium
14.8.1 Business Overview
14.8.2 Radioligand Therapy Portfolio
14.8.3 Pipeline
14.8.4 Manufacturing Capabilities
14.8.5 Strategic Developments
14.8.6 SWOT Analysis
14.9 Lantheus Holdings, Inc.
14.9.1 Business Overview
14.9.2 Financial Overview
14.9.3 Radioligand Therapy Portfolio
14.9.4 Pipeline
14.9.5 Manufacturing Capabilities
14.9.6 Strategic Developments
14.9.7 SWOT Analysis
14.10 Perspective Therapeutics, Inc.
14.10.1 Business Overview
14.10.2 Financial Overview
14.10.3 Radioligand Therapy Portfolio
14.10.4 Pipeline
14.10.5 Manufacturing Capabilities
14.10.6 Strategic Developments
14.10.7 SWOT Analysis
14.11 Orano Med
14.11.1 Business Overview
14.11.2 Radioligand Therapy Portfolio
14.11.3 Pipeline
14.11.4 Manufacturing Capabilities
14.11.5 Strategic Developments
14.11.6 SWOT Analysis
14.12 RadioMedix, Inc.
14.12.1 Business Overview
14.12.2 Radioligand Therapy Portfolio
14.12.3 Pipeline
14.12.4 Manufacturing Capabilities
14.12.5 Strategic Developments
14.12.6 SWOT Analysis
14.13 Clarity Pharmaceuticals Ltd
14.13.1 Business Overview
14.13.2 Financial Overview
14.13.3 Radioligand Therapy Portfolio
14.13.4 Pipeline
14.13.5 Manufacturing Capabilities
14.13.6 Strategic Developments
14.13.7 SWOT Analysis
14.14 Sanofi
14.14.1 Business Overview
14.14.2 Financial Overview
14.14.3 Radioligand Therapy Portfolio
14.14.4 Pipeline
14.14.5 Strategic Developments
14.14.6 SWOT Analysis
15 APPENDIX
15.1 Related Reports
15.2 Customization Options
15.2 Customization Options
List of Tables
Table 1. Global Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 2. Global Radioligand Therapy Market for Pluvicto, By Country/Region, 2024-2036 (USD Million)
Table 3. Global Radioligand Therapy Market for Lutathera, By Country/Region, 2024-2036 (USD Million)
Table 4. Global Radioligand Therapy Market for Xofigo, By Country/Region, 2024-2036 (USD Million)
Table 5. Global Radioligand Therapy Market for Lutetium-177 Edotreotide, By Country/Region, 2024-2036 (USD Million)
Table 6. Global Radioligand Therapy Market for 177Lu-PSMA-I&T, By Country/Region, 2024-2036 (USD Million)
Table 7. Global Radioligand Therapy Market for Actinium-225 PSMA-617, By Country/Region, 2024-2036 (USD Million)
Table 8. Global Radioligand Therapy Market for FPI-2265, By Country/Region, 2024-2036 (USD Million)
Table 9. Global Radioligand Therapy Market for TLX591, By Country/Region, 2024-2036 (USD Million)
Table 10. Global Radioligand Therapy Market for 225Ac-DOTATATE, By Country/Region, 2024-2036 (USD Million)
Table 11. Global Radioligand Therapy Market for AlphaMedix, By Country/Region, 2024-2036 (USD Million)
Table 12. Global Radioligand Therapy Market for 67Cu-SAR-bisPSMA, By Country/Region, 2024-2036 (USD Million)
Table 13. Global Radioligand Therapy Market for Other Radioligand Therapies, By Country/Region, 2024-2036 (USD Million)
Table 14. Global Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 15. Global Lutetium-177 Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 16. Global Actinium-225 Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 17. Global Radium-223 Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 18. Global Lead-212 Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 19. Global Radioligand Therapy Market for Other Radionuclides, By Country/Region, 2024-2036 (USD Million)
Table 20. Global Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 21. Global Beta Emitter Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 22. Global Alpha Emitter Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 23. Global Radioligand Therapy Market for Other Emitters, By Country/Region, 2024-2036 (USD Million)
Table 24. Global Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 25. Global PSMA-Targeted Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 26. Global SSTR-Targeted Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 27. Global Bone Mineral-Targeted Radiopharmaceutical Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 28. Global FAP-Targeted Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 29. Global Radioligand Therapy Market for Other Emerging Targets, By Country/Region, 2024-2036 (USD Million)
Table 30. Global Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 31. Global Radioligand Therapy Market for Prostate Cancer, By Type, 2024-2036 (USD Million)
Table 32. Global Radioligand Therapy Market for Prostate Cancer, By Country/Region, 2024-2036 (USD Million)
Table 33. Global Radioligand Therapy Market for Neuroendocrine Tumors, By Type, 2024-2036 (USD Million)
Table 34. Global Radioligand Therapy Market for Neuroendocrine Tumors, By Country/Region, 2024-2036 (USD Million)
Table 35. Global Radioligand Therapy Market for Other Solid Tumors, By Country/Region, 2024-2036 (USD Million)
Table 36. Global Radioligand Therapy Market for Other Indications, By Country/Region, 2024-2036 (USD Million)
Table 37. Global Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 38. Global First-Line Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 39. Global Second-Line Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 40. Global Third-Line & Later Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 41. Global Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 42. Global Radioligand Therapy Market for Academic & Comprehensive Cancer Centers, By Country/Region, 2024-2036 (USD Million)
Table 43. Global Radioligand Therapy Market for Community Hospitals, By Country/Region, 2024-2036 (USD Million)
Table 44. Global Radioligand Therapy Market for Specialized Nuclear Medicine Centers, By Country/Region, 2024-2036 (USD Million)
Table 45. Global Radioligand Therapy Market for Other End Users, By Country/Region, 2024-2036 (USD Million)
Table 46. Global Radioligand Therapy Market, By Region, 2024-2036 (USD Million)
Table 47. Global Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 48. North America: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 49. North America: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 50. North America: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 51. North America: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 52. North America: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 53. North America: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 54. North America: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 55. North America: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 56. U.S.: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 57. U.S.: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 58. U.S.: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 59. U.S.: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 60. U.S.: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 61. U.S.: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 62. U.S.: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 63. Canada: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 64. Canada: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 65. Canada: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 66. Canada: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 67. Canada: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 68. Canada: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 69. Canada: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 70. Europe: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 71. Europe: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 72. Europe: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 73. Europe: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 74. Europe: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 75. Europe: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 76. Europe: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 77. Europe: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 78. Germany: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 79. Germany: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 80. Germany: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 81. Germany: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 82. Germany: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 83. Germany: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 84. Germany: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 85. U.K.: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 86. U.K.: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 87. U.K.: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 88. U.K.: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 89. U.K.: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 90. U.K.: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 91. U.K.: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 92. France: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 93. France: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 94. France: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 95. France: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 96. France: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 97. France: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 98. France: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 99. Italy: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 100. Italy: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 101. Italy: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 102. Italy: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 103. Italy: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 104. Italy: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 105. Italy: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 106. Spain: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 107. Spain: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 108. Spain: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 109. Spain: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 110. Spain: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 111. Spain: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 112. Spain: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 113. Switzerland: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 114. Switzerland: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 115. Switzerland: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 116. Switzerland: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 117. Switzerland: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 118. Switzerland: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 119. Switzerland: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 120. Netherlands: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 121. Netherlands: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 122. Netherlands: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 123. Netherlands: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 124. Netherlands: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 125. Netherlands: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 126. Netherlands: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 127. Belgium: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 128. Belgium: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 129. Belgium: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 130. Belgium: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 131. Belgium: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 132. Belgium: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 133. Belgium: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 134. Sweden: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 135. Sweden: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 136. Sweden: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 137. Sweden: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 138. Sweden: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 139. Sweden: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 140. Sweden: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 141. Rest of Europe: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 142. Rest of Europe: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 143. Rest of Europe: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 144. Rest of Europe: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 145. Rest of Europe: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 146. Rest of Europe: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 147. Rest of Europe: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 148. Asia-Pacific: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 149. Asia-Pacific: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 150. Asia-Pacific: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 151. Asia-Pacific: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 152. Asia-Pacific: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 153. Asia-Pacific: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 154. Asia-Pacific: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 155. Asia-Pacific: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 156. China: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 157. China: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 158. China: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 159. China: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 160. China: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 161. China: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 162. China: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 163. Japan: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 164. Japan: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 165. Japan: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 166. Japan: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 167. Japan: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 168. Japan: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 169. Japan: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 170. India: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 171. India: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 172. India: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 173. India: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 174. India: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 175. India: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 176. India: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 177. South Korea: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 178. South Korea: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 179. South Korea: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 180. South Korea: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 181. South Korea: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 182. South Korea: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 183. South Korea: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 184. Australia: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 185. Australia: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 186. Australia: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 187. Australia: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 188. Australia: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 189. Australia: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 190. Australia: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 191. Singapore: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 192. Singapore: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 193. Singapore: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 194. Singapore: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 195. Singapore: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 196. Singapore: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 197. Singapore: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 198. Taiwan: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 199. Taiwan: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 200. Taiwan: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 201. Taiwan: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 202. Taiwan: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 203. Taiwan: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 204. Taiwan: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 205. Rest of Asia-Pacific: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 206. Rest of Asia-Pacific: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 207. Rest of Asia-Pacific: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 208. Rest of Asia-Pacific: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 209. Rest of Asia-Pacific: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 210. Rest of Asia-Pacific: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 211. Rest of Asia-Pacific: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 212. Latin America: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 213. Latin America: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 214. Latin America: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 215. Latin America: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 216. Latin America: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 217. Latin America: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 218. Latin America: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 219. Latin America: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 220. Brazil: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 221. Brazil: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 222. Brazil: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 223. Brazil: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 224. Brazil: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 225. Brazil: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 226. Brazil: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 227. Mexico: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 228. Mexico: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 229. Mexico: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 230. Mexico: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 231. Mexico: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 232. Mexico: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 233. Mexico: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 234. Argentina: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 235. Argentina: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 236. Argentina: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 237. Argentina: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 238. Argentina: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 239. Argentina: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 240. Argentina: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 241. Rest of Latin America: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 242. Rest of Latin America: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 243. Rest of Latin America: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 244. Rest of Latin America: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 245. Rest of Latin America: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 246. Rest of Latin America: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 247. Rest of Latin America: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 248. Middle East & Africa: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 249. Middle East & Africa: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 250. Middle East & Africa: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 251. Middle East & Africa: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 252. Middle East & Africa: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 253. Middle East & Africa: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 254. Middle East & Africa: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 255. Middle East & Africa: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 256. U.A.E.: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 257. U.A.E.: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 258. U.A.E.: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 259. U.A.E.: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 260. U.A.E.: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 261. U.A.E.: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 262. U.A.E.: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 263. Saudi Arabia: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 264. Saudi Arabia: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 265. Saudi Arabia: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 266. Saudi Arabia: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 267. Saudi Arabia: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 268. Saudi Arabia: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 269. Saudi Arabia: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 270. Israel: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 271. Israel: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 272. Israel: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 273. Israel: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 274. Israel: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 275. Israel: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 276. Israel: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 277. South Africa: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 278. South Africa: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 279. South Africa: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 280. South Africa: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 281. South Africa: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 282. South Africa: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 283. South Africa: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 284. Rest of Middle East & Africa: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 285. Rest of Middle East & Africa: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 286. Rest of Middle East & Africa: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 287. Rest of Middle East & Africa: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 288. Rest of Middle East & Africa: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 289. Rest of Middle East & Africa: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 290. Rest of Middle East & Africa: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 291. Recent Developments, By Company (2023-2026)
Table 292. Radioligand Therapy Market: Competitive Benchmarking, By Radionuclide
Table 293. Radioligand Therapy Market: Competitive Benchmarking, By Molecular Target
Table 294. Radioligand Therapy Market: Competitive Benchmarking, By Commercial & Development Stage
Table 295. Novartis AG: Radioligand Therapy Portfolio
Table 296. Novartis AG: Strategic Developments (2023-2026)
Table 297. Bayer AG: Radioligand Therapy Portfolio
Table 298. Eli Lilly and Company: Radioligand Therapy Portfolio
Table 299. Eli Lilly and Company: Strategic Developments (2023-2026)
Table 300. Bristol Myers Squibb Company: Radioligand Therapy Portfolio
Table 301. Bristol Myers Squibb Company: Strategic Developments (2023-2026)
Table 302. AstraZeneca PLC: Radioligand Therapy Portfolio
Table 303. AstraZeneca PLC: Strategic Developments (2023-2026)
Table 304. Telix Pharmaceuticals Limited: Radioligand Therapy and Theranostics Portfolio
Table 305. Telix Pharmaceuticals Limited: Strategic Developments (2023-2026)
Table 306. ITM Isotope Technologies Munich SE: Radioligand Therapy Portfolio
Table 307. ITM Isotope Technologies Munich SE: Strategic Developments (2023-2026)
Table 308. Curium: Radioligand Therapy Portfolio
Table 309. Curium: Strategic Developments (2023-2026)
Table 310. Lantheus Holdings, Inc.: Radioligand Therapy and Theranostics Portfolio
Table 311. Lantheus Holdings, Inc.: Strategic Developments (2023-2026)
Table 312. Perspective Therapeutics, Inc.: Radioligand Therapy Portfolio
Table 313. Perspective Therapeutics, Inc.: Strategic Developments (2023-2026)
Table 314. Orano Med: Radioligand Therapy Portfolio
Table 315. Orano Med: Strategic Developments (2023-2026)
Table 316. RadioMedix, Inc.: Radioligand Therapy Portfolio
Table 317. RadioMedix, Inc.: Strategic Developments (2023-2026)
Table 318. Clarity Pharmaceuticals Ltd: Radioligand Therapy and Theranostics Portfolio
Table 319. Clarity Pharmaceuticals Ltd: Strategic Developments (2023-2026)
Table 320. Sanofi: Radioligand Therapy Portfolio
Table 321. Sanofi: Strategic Developments (2023-2026)
Table 2. Global Radioligand Therapy Market for Pluvicto, By Country/Region, 2024-2036 (USD Million)
Table 3. Global Radioligand Therapy Market for Lutathera, By Country/Region, 2024-2036 (USD Million)
Table 4. Global Radioligand Therapy Market for Xofigo, By Country/Region, 2024-2036 (USD Million)
Table 5. Global Radioligand Therapy Market for Lutetium-177 Edotreotide, By Country/Region, 2024-2036 (USD Million)
Table 6. Global Radioligand Therapy Market for 177Lu-PSMA-I&T, By Country/Region, 2024-2036 (USD Million)
Table 7. Global Radioligand Therapy Market for Actinium-225 PSMA-617, By Country/Region, 2024-2036 (USD Million)
Table 8. Global Radioligand Therapy Market for FPI-2265, By Country/Region, 2024-2036 (USD Million)
Table 9. Global Radioligand Therapy Market for TLX591, By Country/Region, 2024-2036 (USD Million)
Table 10. Global Radioligand Therapy Market for 225Ac-DOTATATE, By Country/Region, 2024-2036 (USD Million)
Table 11. Global Radioligand Therapy Market for AlphaMedix, By Country/Region, 2024-2036 (USD Million)
Table 12. Global Radioligand Therapy Market for 67Cu-SAR-bisPSMA, By Country/Region, 2024-2036 (USD Million)
Table 13. Global Radioligand Therapy Market for Other Radioligand Therapies, By Country/Region, 2024-2036 (USD Million)
Table 14. Global Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 15. Global Lutetium-177 Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 16. Global Actinium-225 Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 17. Global Radium-223 Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 18. Global Lead-212 Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 19. Global Radioligand Therapy Market for Other Radionuclides, By Country/Region, 2024-2036 (USD Million)
Table 20. Global Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 21. Global Beta Emitter Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 22. Global Alpha Emitter Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 23. Global Radioligand Therapy Market for Other Emitters, By Country/Region, 2024-2036 (USD Million)
Table 24. Global Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 25. Global PSMA-Targeted Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 26. Global SSTR-Targeted Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 27. Global Bone Mineral-Targeted Radiopharmaceutical Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 28. Global FAP-Targeted Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 29. Global Radioligand Therapy Market for Other Emerging Targets, By Country/Region, 2024-2036 (USD Million)
Table 30. Global Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 31. Global Radioligand Therapy Market for Prostate Cancer, By Type, 2024-2036 (USD Million)
Table 32. Global Radioligand Therapy Market for Prostate Cancer, By Country/Region, 2024-2036 (USD Million)
Table 33. Global Radioligand Therapy Market for Neuroendocrine Tumors, By Type, 2024-2036 (USD Million)
Table 34. Global Radioligand Therapy Market for Neuroendocrine Tumors, By Country/Region, 2024-2036 (USD Million)
Table 35. Global Radioligand Therapy Market for Other Solid Tumors, By Country/Region, 2024-2036 (USD Million)
Table 36. Global Radioligand Therapy Market for Other Indications, By Country/Region, 2024-2036 (USD Million)
Table 37. Global Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 38. Global First-Line Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 39. Global Second-Line Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 40. Global Third-Line & Later Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 41. Global Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 42. Global Radioligand Therapy Market for Academic & Comprehensive Cancer Centers, By Country/Region, 2024-2036 (USD Million)
Table 43. Global Radioligand Therapy Market for Community Hospitals, By Country/Region, 2024-2036 (USD Million)
Table 44. Global Radioligand Therapy Market for Specialized Nuclear Medicine Centers, By Country/Region, 2024-2036 (USD Million)
Table 45. Global Radioligand Therapy Market for Other End Users, By Country/Region, 2024-2036 (USD Million)
Table 46. Global Radioligand Therapy Market, By Region, 2024-2036 (USD Million)
Table 47. Global Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 48. North America: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 49. North America: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 50. North America: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 51. North America: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 52. North America: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 53. North America: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 54. North America: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 55. North America: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 56. U.S.: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 57. U.S.: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 58. U.S.: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 59. U.S.: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 60. U.S.: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 61. U.S.: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 62. U.S.: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 63. Canada: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 64. Canada: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 65. Canada: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 66. Canada: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 67. Canada: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 68. Canada: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 69. Canada: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 70. Europe: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 71. Europe: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 72. Europe: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 73. Europe: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 74. Europe: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 75. Europe: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 76. Europe: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 77. Europe: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 78. Germany: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 79. Germany: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 80. Germany: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 81. Germany: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 82. Germany: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 83. Germany: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 84. Germany: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 85. U.K.: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 86. U.K.: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 87. U.K.: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 88. U.K.: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 89. U.K.: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 90. U.K.: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 91. U.K.: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 92. France: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 93. France: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 94. France: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 95. France: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 96. France: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 97. France: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 98. France: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 99. Italy: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 100. Italy: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 101. Italy: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 102. Italy: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 103. Italy: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 104. Italy: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 105. Italy: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 106. Spain: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 107. Spain: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 108. Spain: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 109. Spain: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 110. Spain: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 111. Spain: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 112. Spain: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 113. Switzerland: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 114. Switzerland: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 115. Switzerland: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 116. Switzerland: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 117. Switzerland: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 118. Switzerland: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 119. Switzerland: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 120. Netherlands: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 121. Netherlands: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 122. Netherlands: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 123. Netherlands: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 124. Netherlands: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 125. Netherlands: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 126. Netherlands: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 127. Belgium: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 128. Belgium: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 129. Belgium: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 130. Belgium: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 131. Belgium: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 132. Belgium: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 133. Belgium: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 134. Sweden: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 135. Sweden: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 136. Sweden: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 137. Sweden: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 138. Sweden: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 139. Sweden: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 140. Sweden: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 141. Rest of Europe: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 142. Rest of Europe: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 143. Rest of Europe: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 144. Rest of Europe: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 145. Rest of Europe: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 146. Rest of Europe: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 147. Rest of Europe: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 148. Asia-Pacific: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 149. Asia-Pacific: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 150. Asia-Pacific: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 151. Asia-Pacific: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 152. Asia-Pacific: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 153. Asia-Pacific: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 154. Asia-Pacific: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 155. Asia-Pacific: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 156. China: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 157. China: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 158. China: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 159. China: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 160. China: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 161. China: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 162. China: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 163. Japan: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 164. Japan: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 165. Japan: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 166. Japan: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 167. Japan: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 168. Japan: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 169. Japan: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 170. India: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 171. India: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 172. India: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 173. India: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 174. India: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 175. India: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 176. India: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 177. South Korea: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 178. South Korea: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 179. South Korea: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 180. South Korea: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 181. South Korea: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 182. South Korea: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 183. South Korea: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 184. Australia: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 185. Australia: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 186. Australia: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 187. Australia: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 188. Australia: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 189. Australia: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 190. Australia: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 191. Singapore: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 192. Singapore: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 193. Singapore: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 194. Singapore: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 195. Singapore: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 196. Singapore: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 197. Singapore: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 198. Taiwan: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 199. Taiwan: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 200. Taiwan: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 201. Taiwan: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 202. Taiwan: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 203. Taiwan: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 204. Taiwan: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 205. Rest of Asia-Pacific: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 206. Rest of Asia-Pacific: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 207. Rest of Asia-Pacific: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 208. Rest of Asia-Pacific: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 209. Rest of Asia-Pacific: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 210. Rest of Asia-Pacific: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 211. Rest of Asia-Pacific: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 212. Latin America: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 213. Latin America: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 214. Latin America: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 215. Latin America: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 216. Latin America: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 217. Latin America: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 218. Latin America: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 219. Latin America: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 220. Brazil: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 221. Brazil: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 222. Brazil: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 223. Brazil: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 224. Brazil: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 225. Brazil: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 226. Brazil: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 227. Mexico: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 228. Mexico: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 229. Mexico: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 230. Mexico: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 231. Mexico: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 232. Mexico: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 233. Mexico: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 234. Argentina: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 235. Argentina: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 236. Argentina: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 237. Argentina: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 238. Argentina: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 239. Argentina: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 240. Argentina: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 241. Rest of Latin America: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 242. Rest of Latin America: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 243. Rest of Latin America: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 244. Rest of Latin America: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 245. Rest of Latin America: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 246. Rest of Latin America: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 247. Rest of Latin America: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 248. Middle East & Africa: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
Table 249. Middle East & Africa: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 250. Middle East & Africa: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 251. Middle East & Africa: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 252. Middle East & Africa: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 253. Middle East & Africa: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 254. Middle East & Africa: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 255. Middle East & Africa: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 256. U.A.E.: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 257. U.A.E.: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 258. U.A.E.: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 259. U.A.E.: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 260. U.A.E.: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 261. U.A.E.: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 262. U.A.E.: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 263. Saudi Arabia: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 264. Saudi Arabia: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 265. Saudi Arabia: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 266. Saudi Arabia: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 267. Saudi Arabia: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 268. Saudi Arabia: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 269. Saudi Arabia: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 270. Israel: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 271. Israel: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 272. Israel: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 273. Israel: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 274. Israel: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 275. Israel: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 276. Israel: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 277. South Africa: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 278. South Africa: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 279. South Africa: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 280. South Africa: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 281. South Africa: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 282. South Africa: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 283. South Africa: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 284. Rest of Middle East & Africa: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
Table 285. Rest of Middle East & Africa: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
Table 286. Rest of Middle East & Africa: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
Table 287. Rest of Middle East & Africa: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
Table 288. Rest of Middle East & Africa: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
Table 289. Rest of Middle East & Africa: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
Table 290. Rest of Middle East & Africa: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
Table 291. Recent Developments, By Company (2023-2026)
Table 292. Radioligand Therapy Market: Competitive Benchmarking, By Radionuclide
Table 293. Radioligand Therapy Market: Competitive Benchmarking, By Molecular Target
Table 294. Radioligand Therapy Market: Competitive Benchmarking, By Commercial & Development Stage
Table 295. Novartis AG: Radioligand Therapy Portfolio
Table 296. Novartis AG: Strategic Developments (2023-2026)
Table 297. Bayer AG: Radioligand Therapy Portfolio
Table 298. Eli Lilly and Company: Radioligand Therapy Portfolio
Table 299. Eli Lilly and Company: Strategic Developments (2023-2026)
Table 300. Bristol Myers Squibb Company: Radioligand Therapy Portfolio
Table 301. Bristol Myers Squibb Company: Strategic Developments (2023-2026)
Table 302. AstraZeneca PLC: Radioligand Therapy Portfolio
Table 303. AstraZeneca PLC: Strategic Developments (2023-2026)
Table 304. Telix Pharmaceuticals Limited: Radioligand Therapy and Theranostics Portfolio
Table 305. Telix Pharmaceuticals Limited: Strategic Developments (2023-2026)
Table 306. ITM Isotope Technologies Munich SE: Radioligand Therapy Portfolio
Table 307. ITM Isotope Technologies Munich SE: Strategic Developments (2023-2026)
Table 308. Curium: Radioligand Therapy Portfolio
Table 309. Curium: Strategic Developments (2023-2026)
Table 310. Lantheus Holdings, Inc.: Radioligand Therapy and Theranostics Portfolio
Table 311. Lantheus Holdings, Inc.: Strategic Developments (2023-2026)
Table 312. Perspective Therapeutics, Inc.: Radioligand Therapy Portfolio
Table 313. Perspective Therapeutics, Inc.: Strategic Developments (2023-2026)
Table 314. Orano Med: Radioligand Therapy Portfolio
Table 315. Orano Med: Strategic Developments (2023-2026)
Table 316. RadioMedix, Inc.: Radioligand Therapy Portfolio
Table 317. RadioMedix, Inc.: Strategic Developments (2023-2026)
Table 318. Clarity Pharmaceuticals Ltd: Radioligand Therapy and Theranostics Portfolio
Table 319. Clarity Pharmaceuticals Ltd: Strategic Developments (2023-2026)
Table 320. Sanofi: Radioligand Therapy Portfolio
Table 321. Sanofi: Strategic Developments (2023-2026)
List of Figures
Figure 1. Radioligand Therapy Market Ecosystem
Figure 2. Currency Conversion Rates Used in the Study (Annual Average Exchange Rates, 2024-2025)
Figure 3. Key Stakeholders in the Radioligand Therapy Market
Figure 4. Research Process
Figure 5. Secondary Sources Referenced for This Study
Figure 6. Primary Research Techniques
Figure 7. Key Executives Interviewed
Figure 8. Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 9. Market Sizing and Growth Forecast Approach
Figure 10. Data Triangulation
Figure 11. Global Radioligand Therapy Market, By Product/Radioligand, 2026 Vs. 2036 (USD Million)
Figure 12. Global Radioligand Therapy Market, By Radionuclide, 2026 Vs. 2036 (USD Million)
Figure 13. Global Radioligand Therapy Market, By Radiation Type, 2026 Vs. 2036 (USD Million)
Figure 14. Global Radioligand Therapy Market, By Molecular Target, 2026 Vs. 2036 (USD Million)
Figure 15. Global Radioligand Therapy Market, By Indication, 2026 Vs. 2036 (USD Million)
Figure 16. Global Radioligand Therapy Market, By Treatment Line, 2026 Vs. 2036 (USD Million)
Figure 17. Global Radioligand Therapy Market, By End User, 2026 Vs. 2036 (USD Million)
Figure 18. Global Radioligand Therapy Market, By Geography, 2026 Vs. 2036 (USD Million)
Figure 19. Radioligand Therapy Treatment Workflow
Figure 20. Components of a Radioligand Therapy
Figure 21. Impact Analysis of Market Dynamics
Figure 22. Regulatory Framework for Radioligand Therapy
Figure 23. Porter's Five Forces Analysis - Radioligand Therapy Market
Figure 24. Global Radioligand Therapy Market, By Product/Radioligand, 2026 Share and CAGR (2026-2036)
Figure 25. Global Radioligand Therapy Market, By Radionuclide, 2026 Share and CAGR (2026-2036)
Figure 26. Key Therapeutic Radionuclides Used in Radioligand Therapy
Figure 27. Global Radioligand Therapy Market, By Radiation Type, 2026 Share and CAGR (2026-2036)
Figure 28. Global Radioligand Therapy Market, By Molecular Target, 2026 Share and CAGR (2026-2036)
Figure 29. Global Radioligand Therapy Market, By Indication, 2026 Share and CAGR (2026-2036)
Figure 30. Global Radioligand Therapy Market, By Treatment Line, 2026 Share and CAGR (2026-2036)
Figure 31. Global Radioligand Therapy Market, By End User, 2026 Share and CAGR (2026-2036)
Figure 32. Global Radioligand Therapy Market: Top 15 Countries/Sub-Regions, 2026 Vs. 2036 (USD Million)
Figure 33. North America: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
Figure 34. Europe: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
Figure 35. Asia-Pacific: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
Figure 36. Latin America: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
Figure 37. Middle East & Africa: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
Figure 38. Key Growth Strategies Adopted By Leading Market Players (2023-2026)
Figure 39. Competitive Dashboard: Radioligand Therapy Market
Figure 40. Global Radioligand Therapy Market Ranking Analysis, By Key Player (2025)
Figure 41. Novartis AG: Financial Snapshot
Figure 42. Novartis AG: SWOT Analysis
Figure 43. Bayer AG: Financial Snapshot
Figure 44. Bayer AG: SWOT Analysis
Figure 45. Eli Lilly and Company: Financial Snapshot
Figure 46. Eli Lilly and Company: SWOT Analysis
Figure 47. Bristol Myers Squibb Company: Financial Snapshot
Figure 48. Bristol Myers Squibb Company: SWOT Analysis
Figure 49. AstraZeneca PLC: Financial Snapshot
Figure 50. AstraZeneca PLC: SWOT Analysis
Figure 51. Telix Pharmaceuticals Limited: Financial Snapshot
Figure 52. Telix Pharmaceuticals Limited: SWOT Analysis
Figure 53. ITM Isotope Technologies Munich SE: SWOT Analysis
Figure 54. Curium: SWOT Analysis
Figure 55. Lantheus Holdings, Inc.: Financial Snapshot
Figure 56. Lantheus Holdings, Inc.: SWOT Analysis
Figure 57. Perspective Therapeutics, Inc.: SWOT Analysis
Figure 58. Orano Med: SWOT Analysis
Figure 59. RadioMedix, Inc.: SWOT Analysis
Figure 60. Clarity Pharmaceuticals Ltd: SWOT Analysis
Figure 61. Sanofi: Financial Snapshot
Figure 62. Sanofi: SWOT Analysis
Figure 2. Currency Conversion Rates Used in the Study (Annual Average Exchange Rates, 2024-2025)
Figure 3. Key Stakeholders in the Radioligand Therapy Market
Figure 4. Research Process
Figure 5. Secondary Sources Referenced for This Study
Figure 6. Primary Research Techniques
Figure 7. Key Executives Interviewed
Figure 8. Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 9. Market Sizing and Growth Forecast Approach
Figure 10. Data Triangulation
Figure 11. Global Radioligand Therapy Market, By Product/Radioligand, 2026 Vs. 2036 (USD Million)
Figure 12. Global Radioligand Therapy Market, By Radionuclide, 2026 Vs. 2036 (USD Million)
Figure 13. Global Radioligand Therapy Market, By Radiation Type, 2026 Vs. 2036 (USD Million)
Figure 14. Global Radioligand Therapy Market, By Molecular Target, 2026 Vs. 2036 (USD Million)
Figure 15. Global Radioligand Therapy Market, By Indication, 2026 Vs. 2036 (USD Million)
Figure 16. Global Radioligand Therapy Market, By Treatment Line, 2026 Vs. 2036 (USD Million)
Figure 17. Global Radioligand Therapy Market, By End User, 2026 Vs. 2036 (USD Million)
Figure 18. Global Radioligand Therapy Market, By Geography, 2026 Vs. 2036 (USD Million)
Figure 19. Radioligand Therapy Treatment Workflow
Figure 20. Components of a Radioligand Therapy
Figure 21. Impact Analysis of Market Dynamics
Figure 22. Regulatory Framework for Radioligand Therapy
Figure 23. Porter's Five Forces Analysis - Radioligand Therapy Market
Figure 24. Global Radioligand Therapy Market, By Product/Radioligand, 2026 Share and CAGR (2026-2036)
Figure 25. Global Radioligand Therapy Market, By Radionuclide, 2026 Share and CAGR (2026-2036)
Figure 26. Key Therapeutic Radionuclides Used in Radioligand Therapy
Figure 27. Global Radioligand Therapy Market, By Radiation Type, 2026 Share and CAGR (2026-2036)
Figure 28. Global Radioligand Therapy Market, By Molecular Target, 2026 Share and CAGR (2026-2036)
Figure 29. Global Radioligand Therapy Market, By Indication, 2026 Share and CAGR (2026-2036)
Figure 30. Global Radioligand Therapy Market, By Treatment Line, 2026 Share and CAGR (2026-2036)
Figure 31. Global Radioligand Therapy Market, By End User, 2026 Share and CAGR (2026-2036)
Figure 32. Global Radioligand Therapy Market: Top 15 Countries/Sub-Regions, 2026 Vs. 2036 (USD Million)
Figure 33. North America: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
Figure 34. Europe: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
Figure 35. Asia-Pacific: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
Figure 36. Latin America: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
Figure 37. Middle East & Africa: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
Figure 38. Key Growth Strategies Adopted By Leading Market Players (2023-2026)
Figure 39. Competitive Dashboard: Radioligand Therapy Market
Figure 40. Global Radioligand Therapy Market Ranking Analysis, By Key Player (2025)
Figure 41. Novartis AG: Financial Snapshot
Figure 42. Novartis AG: SWOT Analysis
Figure 43. Bayer AG: Financial Snapshot
Figure 44. Bayer AG: SWOT Analysis
Figure 45. Eli Lilly and Company: Financial Snapshot
Figure 46. Eli Lilly and Company: SWOT Analysis
Figure 47. Bristol Myers Squibb Company: Financial Snapshot
Figure 48. Bristol Myers Squibb Company: SWOT Analysis
Figure 49. AstraZeneca PLC: Financial Snapshot
Figure 50. AstraZeneca PLC: SWOT Analysis
Figure 51. Telix Pharmaceuticals Limited: Financial Snapshot
Figure 52. Telix Pharmaceuticals Limited: SWOT Analysis
Figure 53. ITM Isotope Technologies Munich SE: SWOT Analysis
Figure 54. Curium: SWOT Analysis
Figure 55. Lantheus Holdings, Inc.: Financial Snapshot
Figure 56. Lantheus Holdings, Inc.: SWOT Analysis
Figure 57. Perspective Therapeutics, Inc.: SWOT Analysis
Figure 58. Orano Med: SWOT Analysis
Figure 59. RadioMedix, Inc.: SWOT Analysis
Figure 60. Clarity Pharmaceuticals Ltd: SWOT Analysis
Figure 61. Sanofi: Financial Snapshot
Figure 62. Sanofi: SWOT Analysis
Companies Mentioned
- Novartis AG
- Eli Lilly and Company
- POINT Biopharma Global Inc.
- Telix Pharmaceuticals Limited
- ITM Isotope Technologies Munich SE
- RayzeBio, Inc.
- Perspective Therapeutics, Inc.
- Fusion Pharmaceuticals Inc.
- Curium Pharma
- Eckert & Ziegler SE
- Lantheus Holdings, Inc.
- RadioMedix Inc.
- Orano Med
- Sofie Biosciences, Inc. (U.S.).
